Advancing Tumor-Directed Drug Therapy
Clinical interest in tumor-directed therapy is increasing because of advancements in interventional oncology and growing recognition of the value of treating the primary tumor across the disease spectrum.
NanOlogy is in development of investigational drugs enabled by its proprietary supercritical precipitation (SCP) technology which forms patented large surface area microparticles (LSAMs) of pure drug. Designed for local delivery, NanOlogy LSAMs remain at the disease site releasing molecular drug for weeks with gradual subtoxic clearance.
Clinical results across multiple solid tumors support therapeutic potential in both local and metastatic disease based on sustained tumoricidal response, favorable immunogenic effect, and minimal systemic toxicity.
Learn More About Our Technology
Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies